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Background: The major obstacles to the successful use of individual nutritional compounds as preventive or
therapeutic agents are their efficacy and bioavailability. One approach to overcoming this problem is to use
combinations of nutrients to induce synergistic effects. The objective of this research was to investigate the
synergistic effects of two dietary components: docosahexaenoic acid (DHA), an omega-3 fatty acid present in
cold-water fish, and curcumin (CCM), an herbal nutrient present in turmeric, in an in vivo model of DMBA-induced
mammary tumorigenesis in mice.
Methods: We used the carcinogen DMBA to induce breast tumors in SENCAR mice on control, CCM, DHA, or
DHA + CCM diets. Appearance and tumor progression were monitored daily. The tumors were harvested 15 days
following their first appearance for morphological and immunohistological analysis. Western analysis was performed
to determine expression of maspin and survivin in the tumor tissues. Characterization of tumor growth was
analyzed using appropriate statistical methods. Otherwise all other results are reported as mean ± SD and analyzed
with one-way ANOVA and Tukey’s post hoc procedure.
Results: Analysis of gene microarray data indicates that combined treatment with DHA + CCM altered the profile of
“PAM50” genes in the SK-BR-3 cell line from an ER-/Her-2+ to that resembling a “normal-like” phenotype. The in vivo
studies demonstrated that DHA + CCM treatment reduced the incidence of breast tumors, delayed tumor initiation,
and reduced progression of tumor growth. Dietary treatment had no effect on breast size development, but tumors
from mice on a control diet (untreated) were less differentiated than tumors from mice fed CCM or DHA + CCM
diets. The synergistic effects also led to increased expression of the pro-apoptotic protein, maspin, but reduced
expression of the anti-apoptotic protein, survivin.
Conclusions: The SK-BR-3 cells and DMBA-induced tumors, both with an ER- and Her-2+ phenotype, were affected by
the synergistic interaction of DHA and CCM. This suggests that the specific breast cancer phenotype is an important
factor for predicting efficacy of these nutraceuticals. The combination of DHA and CCM is potentially a dietary
supplemental treatment for some breast cancers, likely dependent upon the molecular phenotype of the cancer.
Keywords: In vivo studies, Cancer cell differentiation, Breast cancer, Tumor incidence, Tumor growth, Maspin, Survivin* Correspondence: rsiddiqu@iuhealth.org
1Cellular Biochemistry Laboratory, Indiana University Health, Indianapolis, IN
46202, USA
2Methodist Research Institute, Indiana University Health, Indianapolis, IN
46202, USA
Full list of author information is available at the end of the article
© 2013 Siddiqui et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Siddiqui et al. BMC Cancer 2013, 13:418 Page 2 of 16
http://www.biomedcentral.com/1471-2407/13/418Background
The idea that dietary changes or diet supplementation
may improve the health of cancer patients or enhance
the effectiveness of existing treatments is compelling
motivation for exploring the activities of dietary com-
pounds. Although natural products are a promising
addition to current toxic anti-cancer drugs, major obsta-
cles exist to the successful use of individual nutritional
compounds as preventive or therapeutic agents: efficacy
and bioavailability. One approach to overcoming these
problems is to use combinations of nutrients with syner-
gistic effects. Given that the human diet consists of mul-
tiple nutrients, it is likely that nutrients in the diet act
synergistically to provide health benefits. In fact, human
diets can routinely encompass many biologically active
small molecules, and evidence for synergy between diet-
ary compounds is emerging [1-3]. The translational
benefit for such molecules derives from a relative lack of
toxic side effects and source material that is inexpensive
and easily accessible relative to synthetic pharmaceuti-
cals. The objective of the present research is to establish
synergistic interaction with a combination of Docosahe-
xaenoic acid (DHA), an omega-3 PUFA found in fish oil,
and curcumin (CCM), a phenolic molecule found in tur-
meric, on breast cancer growth.
Docosahexaenoic acid (22:6Δ4,7,10,13,16,19) is the most
unsaturated of the fatty acids commonly found in bio-
logical systems. Early epidemiological evidence strongly
links fish oil (rich in DHA and eicosapentaenoic acid
[EPA]) with a low incidence of several types of cancer,
including breast cancer [4-7]. In addition to strong epi-
demiological studies, dietary studies have also substanti-
ated DHA’s role as an anti-cancer agent for breast
cancer [8-10]. Curcumin [1,7-bis(4-hydroxy-3-methoxy
phenyl) -1,6-heptadiene-3,5-dione] has been frequently
used in South Asian medicine since the second millen-
nium BCE. Coincidently, a recent study reported that
breast cancer rates in India were significantly lower than
in Western countries, including the US [11]. Preclinical
studies have revealed growth-inhibitory potential of
curcumin in several cancers, including colon, duodenal,
stomach, prostate, and breast [8,12-17].
Breast cancer is a myriad of diseases with multiple
phenotypes. Clinically, breast cancers are subdivided
according to estrogen receptor (ER) and oncogenic Her-
2 status. Progesterone receptor (PR) is another molecu-
lar marker that is also used to predict a lack of response
to hormone therapy [18]. More recent studies using glo-
bal gene expression profiling with widely available
microarray techniques describe distinct molecular sub-
types of breast cancer, each defined by a large number of
genes [19-21]. These include basal-like, Her2-enriched,
normal-like, luminal A, and luminal B subtypes. This
classification has been further refined and now utilizes aset of 50 representative genes known as “PAM50” genes
[22,23]. Those classifications also parallel the established
clinical- and histological-based classifications, with
basal-like representing ER-/Her2-cancers, Her-2 enriched
representing ER-/Her2+, and normal-like and luminal A/
B subtypes representing ER+. With this diverse classifica-
tion, it would be expected that a particular therapeutic
agent or dietary supplement might not be effective for
all malignant subtypes. Although there is a debate about
the advantage of molecular signature classification over
existing surface receptor classification [24-26], the mo-
lecular signature may provide more in-depth knowledge
about the progression of disease or response to treatment.
In a previous study, we used 5 breast cell lines cover-
ing distinct receptor expression phenotypes: MDA-MB-
231 (ER- PR- Her2-), SK-BR-3 (ER- PR- Her2+), MCF7
(ER+ PR+ Her2-), MDA-MB-361 (ER+ PR- Her2+), and
MCF10AT (ER+, PR isoform B but not A, Her2 variable)
[27-30]. Across these cell lines, the synergistic anti-
proliferative effects of CCM, DHA, and a DHA + CCM
combination were assessed quantitatively as described by
Tallarida [31]. Our data demonstrated that the combin-
ation of DHA + CCM (3:2), when less than 50 μM,
exerted a synergistic effect only in the SK-BR-3 breast
cancer cell line. Detection of anti-proliferation synergy
for DHA + CCM within the SK-BR-3 cell line was
followed by transcript analysis using the Agilent Whole
Human Genome Microarray 4×44K platform. The
microarray data and corresponding step-by-step analysis
is posted as supplementary data on the BMC-Cancer
web site [32]. The data demonstrate that the expression
of genes involved in apoptosis, inhibition of metastasis,
and cell adhesion were upregulated, whereas genes in-
volved in cancer development and progression, metasta-
sis, and cell cycle progression were downregulated [32].
Furthermore, a significant 20- to 100-fold increase in
CYP450 class-1, a nearly 20-fold upregulation of
SERPINB5, and a 60% downregulation of BIRC5 gene ex-
pression are of special functional interest. CYP450 pro-
teins are involved in the metabolism of estrogen,
activation/inactivation of carcinogens, and enhancement
of the anti-proliferative effects of polyphenols [33-39].
SERPINB5 protein (also known as maspin, mammary
gland-associated serine protease inhibitor) is a pro-
apoptotic tumor suppressor that is completely suppressed
in most breast cancers but is re-expressed on anti-cancer
treatment [40], whereas the BIRC5 protein (also known as
survivin), belongs to the Inhibitors of Apoptosis Protein
(IAP) family, which is mostly absent from well-
differentiated, normal adult tissues, but is over-expressed
in nearly all human cancers [41]. The fact that only the
SK-BR-3 cell line was synergistically affected by DHA and
CCM suggests that specific breast cancer phenotype is an
important factor for predicting efficacy.
Table 1 Formulation of experimental diets
Corn oil Corn oil + CCM DHASCO DHASCO + CCM
g/Kg
Casein 235 235 235 235
DL-Methionine 3.5 3.5 3.5 3.5
Corn Starch 247 245 247 245
Maltodextrin 130 130 130 130
Dextrose 90 90 90 90
Corn oil 180 180 30 30
DHASCO 0 0 150 150
CCM 0 2 0 2
Celluloase 59 59 59 59
Mineral Mix 41 41 41 41
Vitamin Mix 12 12 12 12
Choline Bitartrate 2.4 2.4 2.4 2.4
Vitamin E (1100 IU/g) 0.0075 0.0075 0.0075 0.0075
Vitamin C (35%) 0.05 0.05 0.05 0.05
Table 2 Fatty acid composition of the experimental diets
Corn oil Corn oil + CCM DHASCO DHASCO + CCM
C14:0 0.13 ± 0.00 0.14 ± 0.00 9.83 ± 0.15 9.62 ± 0.13
C16:0 11.75 ± 0.23 11.75 ± 0.30 10.39 ± 0.14 10.42 ± 0.05
C16:1n-7 0.10 ± 0.00 0.10 ± 0.00 1.88 ± 0.01 1.82 ± 0.02
C18:0 1.70 ± 0.09 1.69 ± 0.02 1.01 ± 0.01 1.34 ± 0.26
C18:1n-9 27.06 ± 0.50 27.03 ± 0.75 23.85 ± 0.31 23.38 ± 0.23
C18:2n-6 56.81 ± 1.04 56.83 ± 1.70 11.11 ± 0.15 10.99 ± 0.16
C18:3n-3 0.94 ± 0.02 0.94 ± 0.03 0.20 ± 0.00 0.20 ± 0.00
C20:0 0.35 ± 0.01 0.35 ± 0.01 0.15 ± 0.01 0.14 ± 0.01
C20:1n-9 0.24 ± 0.01 0.25 ± 0.01 0.10 ± 0.00 0.10 ± 0.00
C20:5n-3 0.06 ± 0.00 0.06 ± 0.00 0.14 ± 0.01 0.13 ± 0.01
C22:6n-3 0.04 ± 0.00 0.03 ± 0.01 34.81 ± 0.73 35.44 ± 0.46
Total-SFA 14.02 ± 0.32 14.03 ± 0.33 26.97 ± 0.41 26.99 ± 0.55
Total MUFA 27.64 ± 0.53 27.63 ± 0.78 24.40 ± 0.38 23.95 ± 0.26
Total n-6 PUFA 56.81 ± 1.00 56.83 ± 1.70 11.11 ± 0.15 10.99 ± 0.16
Total n-3 PUFA 1.05 ± 0.03 1.034 ± 0.04 35.52 ± 0.75 36.15 ± 0.49
n-6/n-3 54 55 0.31 0.30
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understand the response of dietary treatments on
“PAM50” genes. We made initial attempts to test the
synergism between DHA and CCM in a xenograft model
of the SK-BR-3 cell line; however, we were not able to
grow the SK-BR-3 xenograft in nude mice because of
low tumorigenic potential of SK-BR-3 cells. Therefore, in
the present study we present results from an in vivo
study on DMBA-induced ER-negative/Her-2 positive
breast tumors to validate the DHA and CCM synergistic
effects in a similar phenotypic breast cancer.
Methods
Materials
SK-BR-3 cells were obtained from the American
Type Culture Collections (ATCC; Manassas, VA) and
maintained in McCoy’s 5A medium (ATCC) supple-
mented with penicillin (100 units/ml), streptomycin
(100 μg/ml), and 10% FBS. McCoy’s 5A medium, penicil-
lin, streptomycin, and glutamine were from Invitrogen
Corporation (Grand Island, NY). Fetal bovine serum was
from BioWhittaker (Walkersville, MD). DHA (NuChek
Prep, Inc., Elysian, MN) was diluted in 100% ethanol to
make 50 mM stock solutions. CCM (Sigma Aldrich, St.
Louis, MO) was dissolved in DMSO to make 50 mM
stock solutions. The fatty acid standards for gas chroma-
tography (GC) were from Nu-Chek Prep, Inc. (Elysian,
MN). Docosahexaenoic acid single cell oil (DHASO) was
a generous gift from DSM Nutrition (Columbia, MD).
Methanol, chloroform, petroleum ether, diethyl ether,
acetic acid, hexane, and ethanol were from Fisher Scien-
tific (Fair Lane, NY). Anti mouse ER, Her-2 and PR anti-
bodies were from Santa Cruz Biotechnology Inc. (Dallas,
TX). H & E stain and all other reagents were from Sigma
Chemical Co. (St Louis, MO).
Animals and diets
One week after receiving the animals, SENCAR (SENsitive
to CARcinogen) mice (female, 3 weeks old, 25-30 g, Fred-
erick National Laboratory for Cancer Research, National
Cancer Institute, Fredrick, MD) were randomly divided
into 4 groups and fed ad libitum diets containing corn oil
(control diet), corn oil with CCM (CCM-diet), DHASCO
(DHA-diet), or DHASCO with CCM (DHA +CCM-diet)
(Taklad, Harlan laboratories, Madison, WI, USA) for
3 weeks prior to tumor induction. Mice continued feeding
on the corresponding diets and were weighed every week
throughout the study. The diets contained similar quan-
tities of protein (20% of calories), carbohydrates (42% of
calories), lipids (38% of calories), vitamins, and minerals as
described in Table 1. They only differed in the types of
lipids (i.e., corn and DHASCO) and their fatty acids com-
position as described in Table 2. At six weeks of age, the
mice were gavaged with 200 μl of DMBA (1 mg/ml insesame oil) one time per week for six weeks [42,43]. Mice
were examined daily for the appearance of tumor by pal-
pation, and the first day of tumor detection was recorded.
Mice were anesthetized using Isoflurane 15 days after the
first appearance of tumor. A blood specimen was collected
by cardiac puncture, and the tumor was dissected out,
measured, and weighed. Blood and tumor specimens were
stored at −70°C. A portion of the tumor tissues was em-
bedded in OCT (optimal cutting temperature) compound
for immunohistology for ER, PR, and Her-2 expression
and histological evaluation by hematoxylin and eosin
(H&E) stain. The protocol for these studies was approved
(protocol # 2010–22) by the Methodist Research Institute’s
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Number-A3772-010) and strictly followed Guide for the
care and use of laboratory animals (NIH publication
No.85-23, revised 1996).
Whole breast mount
The entire intact lower abdominal mammary gland (#4)
was dissected out and spread on a glass slide for measur-
ing the size and histological evaluation as described [44].
The gland was air dried briefly and then fixed in
Carnoy’s fixative (6 parts 100% ethanol, 3 parts methanol
and 1 part glacial acetic acid) overnight. The mount was
rehydrated in increasing dilutions of ethanol in distilled
water (70%, 50%, 30%, 10%, 0%, 10 minutes each) and
then stained by placing the slide in Carmine Alum stain
over night. The excess stain was removed by washing
with increasing concentrations of ethanol (70%, 95%,
100%, 15 minutes each), and then the slides were placed
in xylene solutions for at least 2 days until the fats were
sufficiently cleared from the gland. The mammary tissue
was mounted using Fluoromount and a glass cover slip.
Images were recorded using a dissecting microscope
(Leica S8APO, Leica Corporation, Switzerland), and
photographs were captured with a digital camera
(MagnaFire, Optronics, Goleta, CA).
Histology
Transverse serial sections of tumor tissues (10 μm) were
prepared using a cryostat (Leica CM1900, Leica
Microsystems, Bannockburn, IL). The analysis of tissue
histology was performed by staining sections with H & E
stain (Sigma Chemical Co., St Louis, MO). Slides were
examined by Dr. Yava Jones in the Department of Com-
parative Pathobiology at Purdue University. The tumors
were classified based on their morphological features as
described by Dunn [45]. For detecting ER, PR, and Her-
2 expression, immunohistology was performed by the
pathological laboratory services of Indiana University
Health (Indianapolis, IN) using mouse specific anti-
estrogen receptor, progesterone receptor, and Her-2
receptor antibodies. Slides were scanned and the expres-
sion of ER, PR, and Her-2 was quantified using Aperio
ImageScope software (Aperio, Vista, CA). The positive
stained area and total scanned area were measured with
precise calibration, and the percent of the positive
stained area was determined. The total scanned area ex-
cludes the uneven tissue edges and void regions without
cells. Expressions of antigens in CCM, DHA, and DHA +
CCM are reported as fold changes compared to control
(corn oil fed animals).
Western blot analysis
The tumor tissues were homogenized in a homogenizing
buffer (0.25 M sucrose, 50 mM Hepes, pH 7.4, 2 mMEGTA) using a polytron homogenizer. The homogenate
was solubilized in 2× lysis buffer (20 mM Tris–HCl,
pH 7.4, 137 mM NaCl, 100 mM NaF, 2 mM Na3VO4,
10% glycerol, 1% nonidet P-40, 2 mM PMSF, 1 μg/mL
leupeptin, 0.15 units/mL aprotinin and 2.5 mM
diisofluorophosphate) for 10 minutes on ice. The deter-
gent solubilized extracts were centrifuged to remove in-
soluble matter. After evaluating the protein content
using a BCA (bicinchoninic acid) Protein Assay Kit
(Pierce, Rockford, IL), 15 μg of protein solubilized in
Laemmli sample-loading buffer was loaded onto each
lane of a 4-12% gradient SDS-polyacrylamide gel and
transferred onto nitrocellulose membranes. Membranes
were blocked for 30 minutes at room temperature in
10% Roche western blocking reagent in Tris buffered sa-
line supplemented with 0.1% Triton X-100 (TBST). Blots
were probed with primary antibodies (anti-maspin, anti-
survivin, Cell Signaling Technology, Danvers, MA; anti-
β-actin, Santa Cruz Biotechnology, Dallas, TX) according
to the manufacturer’s recommendations. Secondary anti-
bodies were peroxidase-conjugated for protein detection
using an enhanced chemiluminescence (ECL) system
(Amersham Pharmacia Biotechnology, Piscataway, NJ,
USA). Nitrocellulose membranes were stripped in
62.5 mM Tris–HCl (pH 6.8) buffer containing 2% SDS
and 100 mM β-mercaptoethanol for 30 minutes at 50°C.
Stripped blots were washed 6 times in TBST, blocked,
and reprobed with an alternative antibody.
Statistical analysis
Data is presented as mean ± SD unless reported other-
wise. The progression of tumor development in different
dietary groups was compared using the Chi-square test,
whereas the number of tumors formed/animal in each
group was compared between groups using one-way
ANOVA with Scheffe post hoc test. Data for time to ini-
tial tumor appearance are summarized as median (Q1,
Q3) and compared between groups using log-rank test.
All other comparisons were made by one-way ANOVA
with Tukey’s post hoc test using IBM SPSS statistics 20
software.
Results
Effect of DHA and CCM on “PAM50” gene expression
We used the microarray data from the SK-BR-3 cell line
to examine the signature profile of “PAM50” genes and
determine if the combined treatment with DHA and
CCM influenced the expression of the gene signature
profile. The data presented by Creighton [46] and
Hoadley [47] represents a modified gene signature pro-
file for breast cancer sub-classification. We selected the
same genes from our microarray data (Figure 1) and ar-
ranged them in a similar manner, as described by
Creighton [46]. We found that the gene signature of
Figure 1 The signature profile of PAM50 gene expression in SK-BR-3 cells. The expression profile of PAM50 genes (40 matching genes)
from microarray data [32] in SK-BR-3 cells treated with vehicle, DHA, CCM or DHA + CCM were used to compare the signature profile of 41 genes
represented on the U133A array system, as reported by Creighton [46], to classify tumors into basal-like, Her-2-enriched, luminal A, luminal B, and
“normal-like.” The expression profile of untreated cells (control) resembled the ER-, Her-2-enriched profile, whereas the expression profile of cells
treated with DHA + CCM more closely resembled the “normal-like” profile.
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file, further confirming our SK-BR-3 cell characte-
rization. DHA alone had very little effect, but CCM
treatment changed the expression of a number of genes.
DHA, however, appears to be acting as a modulator of
the effects of CCM, and it is very intriguing to observe
that the combined DHA + CCM treatment has altered
the SK-BR-3 profile from an ER-/Her-2+ (untreated cell)phenotype to resemble a “normal-like” phenotype. Fur-
thermore, as shown in Table 3, DHA or CCM alone has
no significant effect on ER, Her-2, and PR expression;
however, the DHA and CCM combination caused a
nearly 3-fold increase (P < 0.001) in ER expression,
whereas DHA or CCM alone had no effect. This obser-
vation was further validated in our in vivo experiments
presented below.
Table 3 Changes in estrogen receptor, progesterone
receptor and her-2 oncogenes in SK-BR-3 cell and
DMBA-induced tumors
DHA + CCM P value CCM P value DHA P value
Gene expression (SK-BR-3 cells)
(n = 3) (n = 3) (n = 3)
PGR 1.67 0.628 2.05 0.294 1.16 0.991
ESR-1 2.90 0.00 1 1.04 0.994 1.19 0.581
ERBB2 0.97 0.119 1.01 0.187 1.08 0.227
Protein expression (DMBA-induced tumors)
(n = 4) (n = 10) (n = 10)
PR 0.38 0.913 0.67 0.962 0.80 0.992
ER-alpha 7.50 0.01 3.81 0.219 3.41 0.415
Her-2 2.60 0.261 1.68 0.704 0.97 1.00
Values are fold changes compared to vehicle treated control. The data is
analyzed by one-way ANOVA and Tukey’s post hoc test.
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The data presented in Figure 2 demonstrate that a DHA
or CCM diet alone did not reduce the incidence of
tumor occurrence in mice, whereas the combined DHA
diet with CCM significantly delayed tumor initiation and
also significantly reduced the incidence of breast tumor
in mice. The data presented in Table 4 indicate thatFigure 2 Effect of DHA, CCM, and DHA + CCM on DMBA-
induced breast tumor development. After an acclimation period,
SENCAR mice (NIH, Fredric, MD) were divided into 4 groups
(15/group). Each group was fed a different diet for 3 weeks prior to
tumor induction: 1) 18% corn oil (Brown line); 2) 15% DHASCO
(DSM, Columbia, MD) + 3% corn oil (Light green line); 3) 18% corn
oil + 0.2% curcumin (Orange line); or 4) 15% DHASCO + 3% corn
oil + 0.2% curcumin (Dark green line). Doses of DHA and CCM were
selected based on published data [2]. Mice continued to be fed the
corresponding diet during the entire course of the experiment. Each
mouse was gavaged with 200 μl DMBA (1 mg/ml in sesame oil)
once every week for 6 weeks to induce breast tumors. The
appearance of palpable tumors was monitored daily beginning with
the first DMBA gavage. The statistical analysis and characterization of
the effects of different diets on DMBA-induced breast tumors are
shown in Table 4.about 73% of mice on the corn oil and corn oil + CCM
diets developed tumors, and mice on the DHA diet
yielded a tumor incidence of 67%. However, only 27%
(P = 0.0240) of animals developed tumors when on the
DHA + CCM diet. There was no statistical difference in
the number of tumors per animal within corn oil, CCM,
and DHA groups; however, there were significantly fewer
breast tumors per animal when treatment with DHA
and CCM was combined. In addition, the average tumor
mass (Table 4 & Figure 3) in the DHA + CCM group
was also significantly less (0.3 g) compared to other
groups (1.2 - 1.4 g) (P = 0.026). Furthermore, the length
of time for the initial tumor to appear in animals fed
DHA + CCM was significantly longer (P = 0.018) than
that of animals fed control, DHA, or CCM diets. The
DHA, CCM, or DHA + CCM treatment was non-toxic,
based on the lack of significant differences in body
weights between groups (data not shown).
Effects of curcumin and DHA on breast development
We further investigated if the carcinogen or diet had any
influence on normal mouse breast development by pre-
paring breast whole mounts (Figure 4). The total length
of breast tissue per gram body weight did not differ sig-
nificantly among the dietary groups with or without
DMBA-induced tumors. The total width of breast tissue
per gram body weight was not significantly different
within DMBA-induced or non-DMBA treated animals.
However, the total width of breast tissue per gram body
weight was significantly reduced in animals with CCM
(P = 0.025) or DHA + CCM (P = 0.002) treatment only in
the DMBA-tumor group, whereas the total width of
breast tissue per gram body weight was not different on
these treatments in non-DMBA induced animals. We
also looked at the morphological features of the whole
breast mount from animals on different dietary groups
(Figure 5). The mammary ducts in control animals (corn
oil fed) with DMBA-induced tumors exhibited less dif-
ferentiation of the gland with substantial reduction in
the density of terminal end buds (TEB) compared to ani-
mals fed the other diets. Animals on CCM or DHA diets
also had some reduction in TEB density compared to
control non-tumor-bearing animals, whereas animals on
DHA + CCM diets had well differentiated breast tissues
and the TEB density was similar to that of control, non-
DMBA-induced animals. In addition, we also looked for
the presence of proliferative regions where the alveolar
buds showed extensive staining. Data presented in
Figure 5 show that control animals had an average of 1.3
proliferative lesions per breast. DHA treatment did not
affect the number of the proliferative lesions. Although
non-significant, the CCM diet reduced proliferative le-
sions to 40% (0.5 average proliferative lesions/breast),
and a DHA + CCM diet substantially reduced prolife-
Table 4 Characteristics of DMBA-induced tumors in SENCAR mice on different dietary treatment
Corn oil Corn oil + CCM DHASCO DHASCO + CCM P value
Number of mice developing tumors& 11 (73.3%) 11 (73.3%) 10 (66.7%) 4 (26.7%) 0.024
(n = 15) (n = 15) (n = 15) (n = 15)
Number of tumors/animal# 1.27 ± 1.03 1.20 ± 1.01 0.87 ± 0.74 0.27 ± 0.45 0.036
(n-15) (n = 15) (n = 15) (n = 15)
Tumor weight+ (g) 1.1 ± 0.6 1.3 ± 0.8 1.4 ± 0.3 0.3 ± 0.3 0.026
(n = 11) (n = 11) (n = 10) (n = 4)
Time to tumor development* (days) 80 (70, 87) 87 (73, 108) 92 (77, 101) NE (114, NE) 0.018
(n = 15) (n = 15) (n = 15) (n = 15)
& compared between groups using Chi-square test;
+ compared between groups using ANOVA;
# compared between groups using one-way ANOVA with Scheffe post hoc test.
* Data summarized median (Q1, Q3) and compared between groups using the log-rank test.
NE not estimable.
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breast) (data not shown). However, the total tumor bur-
den, estimated by adding the palpable tumor and prolif-
erative lesion in each breast tissue (Figure 4) showed a
significant 50% reduction (P = 0.028) in breast tissue
from animals fed a DHA + CCM diet compared to the
control group.
Histology of breast tumors
The basic morphological features of tumors were evalu-
ated using H&E stain. The data presented in Figure 6 in-
dicate that control animals on a corn oil diet largely
developed adenosquamous (55%) and ductal (36%) car-
cinomas, with few tumors showing adenocarcinoma type
A (9%). Animals fed a curcumin diet developed mostly
ductal carcinoma (36%) and carcinosarcoma (27%), with
some tumor showing features of adenocarcinoma type A
(18%), whereas only few tumors were adenosquamous
carcinoma or mixed carcinoma type (9%). Interestingly,
animals fed either a DHA or DHA + CCM diet mostly
formed adenosquamous type carcinoma (75%-100%)
with marked central keratinization.Figure 3 Size and location of DMBA-induced tumors in different dieta
the legend of Figure 2. Sites of tumor development in animals fed a corn o
shown by red arrows. Red circles indicate relative tumor sizes.Histological analysis of the tumors indicates that the
DMBA tumors were largely ER-, HER-2+ and PR-
(Figure 7). However, when animals were treated with
CCM or DHA + CCM, these tumors changed their be-
havior and were ER+, Her-2+ and PR-/+ (Figure 7). The
quantitative analysis of ER, Her-2 and PR proteins in
immunohistological slides is shown in Table 3, which in-
dicates that DHA + CCM treatment caused a significant
7.5-fold increase (P = 0.01) in the expression of ER in tu-
mors, whereas none of the other treatments had any ef-
fect on the expression of ER, Her-2, or PR.
Effect of DHA and CCM on maspin and survivin expression
As mentioned above, our micro array data indicated a
20-fold increase in SERPINB5 expression and a 60% re-
duction in BIRC5 genes in SK-BR-3 cells treated with
DHA + CCM compared to the control cells. We, there-
fore, analyzed the expression of maspin (SERPINB5) and
survivin (BIRC5) in tumors from different dietary treat-
ments. As demonstrated in Figure 8 using two represen-
tative tumors, maspin was absent or expressed at a very
low level in a majority of tumors in animals fed either ary groups. The details of animals and tumor induction are given in
il-diet (A), CCM-diet (B), DHA-diet (C) or DHA + CCM-diet (D) are
Figure 4 Effect of diets on DMBA-induced tumors in SENCAR mice. The total length (a+b) and width (c) were measured as indicated in the
total breast mount picture. The total length and width were compared between non-tumor-bearing and DMB-induced tumor groups, whereas as
total tumor burden was calculated by adding the number of palpable tumors (Table 4) and number of proliferative regions (Figure 5) in each
animal within a dietary group. Data is analyzed by oneway ANOVA and Tukey post-hoc test.
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http://www.biomedcentral.com/1471-2407/13/418control (corn oil) or DHA diet; however, a substantial
amount of maspin was expressed in tumors from mice fed a
CCM diet, and its expression was further stimulated in tu-
mors from DHA+CCM fed animals. In contrast, consider-
able survivin expression was observed in tumors from
animals fed a control diet, a DHA-enriched diet, or a CCM-
enriched diet. However, DHA+CCM treatment caused
nearly a 50% reduction in survivin expression in the tumors.
Discussion
About 41% of all newly approved drugs are estimated to
have a nutritional/natural product origin, and about 60% of
these are anti-cancer drugs [48]. However, it is becoming
apparent that the major obstacles to the successful use of
individual nutritional compounds as preventive or thera-
peutic agents are their efficacy and bioavailability. One ap-
proach to overcoming this problem is to use combinations
of nutrients to induce synergistic effects. Traditionally, nu-
tritional compounds in “folk medicine” are used in un-
modified form, as concentrated extracts. Given that the
human diet consists of multiple nutrients, dietary nutrients
likely act synergistically to provide health benefits. Centur-
ies ago Hippocrates stated, “Let food be thy medicine, and
let thy medicine be food." DHA and CCM are natural non-
toxic nutrients that have anti-cancer properties; however,their use as individual compounds is not very efficacious.
Therefore, we tested the possibility that they could act syn-
ergistically. In our previously published in vitro studies, we
used 5 breast cell lines covering distinct receptor expression
phenotypes: MDA-MB-231 (ER- PR- Her2-), SK-BR-3 (ER-
PR- Her2+), MCF7 (ER+ PR+ Her2-), MDA-MB-361 (ER+
PR- Her2+), and MCF10AT (ER+, PR isoform B but not A,
Her2 variable). We found that SK-BR-3, an ER-/Her-2+ cell
line, responded synergistically to the DHA+CCM com-
bined treatment [32]. We further demonstrated that the
synergistic effects of DHA and CCM were mediated
through the activation of NFκB and the expression of
PPARγ. As outlined in the introduction, our gene micro-
array data showed that expression of genes involved in
apoptosis, inhibition of metastasis, and cell adhesion were
upregulated, whereas genes involved in cancer development
and progression, metastasis, and cell cycle progression were
downregulated on the combined DHA+CCM treatment.
Those data suggested that this differential gene expression
by the combined treatment could be effective in limiting
growth of cancerous cells.
In addition, we further analyzed the “PAM50” subset of
genes to validate the breast cancer signature profile of SK-
BR-3 cell lines and to determine if this signature profile
changes in response to the combined DHA+CCM
Figure 5 Effect of diet on the breast tissues morphology. The details of animals and tumor induction are given in the legend of Figure 2.
Breast tissues were isolated from the abdominal region on day 15 after the first appearance of the tumor. Breast tissues from non-tumor-bearing
(NTB) mice with a similar age group were used for comparison. The whole breast mounting was performed as described in the experimental
section. The tissues were observed under a dissecting microscope (Leica S8APO) at 20× magnification and the hyper-proliferative regions (arrows)
in the entire breast tissue were recorded.
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http://www.biomedcentral.com/1471-2407/13/418treatment. As expected, the untreated SK-BR-3 cells
showed a signature pattern for ER-, Her-2+ tumors. Import-
antly, we found that DHA+CCM treatment transformed
the PAM50 gene signature profile towards a “normal-like”
profile (Figure 1) with significant ER expression. This ob-
servation indicates that these compounds act synergistic-
ally to transform a highly undifferentiated tumor into a
differentiated form. We speculate that this concept of
chemically changing the gene profile of tumor into “nor-
mal-like” tissue will open new avenues to identify the key
target genes that may transform a neoplastic cell into a
normal cell. The concept of changing cellular structure
and function has been published when a differentiated cell
was transformed into a stem cell by introducing 4 key
genes [49]. It is possible that a reverse approach may have
high potential for the treatment of tumors.In our previous studies on SK-BR-3 cells, we realized
that treating breast cancer cells in vitro with a combin-
ation of DHA + CCM may reflect a similar response
in vivo. We, therefore, further extended our studies in
an in vivo model of breast cancer. We initially used a
xenograft model of SK-BR-3 tumors in nude mice. Be-
cause of the low tumorigenic potential of SK-BR-3 cells,
these studies could not be completed. We, therefore,
used a DMBA-inducible breast cancer model to deter-
mine the effects of DHA, CCM, and DHA + CCM.
Interestingly, the DMBA-induced breast cancer model
in SENCAR (sensitive to carcinogenesis) mice has been
shown by others [50-53] and validated by us, to exhibit
a phenotype (ER-, Her-2+) similar to that of SK-BR-
3 cells [30]. Therefore, our in vivo model closely resem-
bled our in vitro breast cancer cell model.
Figure 6 Histological characterization of DMBA-induced tumors. The breast tumors were isolated on day 15 after the first appearance of
tumor and embedded in OCT. Transverse serial sections of tumor tissues (10 μm) were prepared using a cryostat (Leica CM1900, Leica
Microsystems, Bannockburn, IL) and the sections were subjected to H & E stain (Sigma Chemical Co., St Louis, MO). The tumors were classified
based on their morphological features as described by Dunn [45].
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http://www.biomedcentral.com/1471-2407/13/418The data presented in Figure 2 demonstrate that DHA
in combination with CCM delays tumor initiation and
reduces the incidence of breast tumors in mice. Mor-
phologically, breast tumors in the DHA + CCM group
appeared to be more differentiated then control tumors.
Additionally, the single treatment with either DHA or
CCM did not alter the TEB, which were similar to the
non-tumor control. No apparent difference was found in
the size (length and width) of normal breast tissue in
any dietary group, indicating that diet itself has no effect
on the development of breast. In contrast, breast tissue
width was significantly reduced in DMBA-induced ani-
mals fed a CCM or DHA + CCM diet. This indicates a
possible interaction of DMBA with CCM, but it is not
clear if this reduction in breast width has any patho-
logical implications.
Both DMBA and CCM are metabolized to their active
metabolites by cytochrome P450 (CYP450) class 1enzymes [54,55]. The expression of these enzymes is dir-
ectly regulated by the activation of Aryl hydrocarbon re-
ceptor (AhR). Both CCM and DMBA bind to AhR to
induce expression of CYP40-class-1 enzymes [56,57]. It
is, therefore, possible that CCM and DMBA may have
interacted at the AhR-CYP450-1 axis and that agonist vs
antagonist effects of DMBA and CCM may have some
growth inhibitory effects on breast development. The
role of CCM and DMBA on AhR activation and the me-
tabolism of CCM and DMBA clearly require further
investigation.
Histological examination of the breast tumors allowed
us to subclassify them into multiple types. The most
common tumor type in control- or CCM-treated ani-
mals was ductal carcinoma (36%); however, the tumors
that developed on a DHA or DHA + CCM diet appeared
to be largely an adenosquamous type with marked cen-
tral keratinization (75-100%). The expression of keratin
Figure 7 Effect of diets on the estrogen receptor, Her-2 oncogene, and progesterone receptor expression in DMBA-induced tumors.
Tumors were isolated and tissue sections were prepared as described in the legend of Figure 6. Expression of estrogen receptor (ER), Her-2
oncogene (Her-2), and progesterone receptor (PR) were detected using specific anti-mouse antibodies. Slides were observed under an Olympus
microscope at 50 × magnification. The quantitative analysis antigen expression is described in Table 3.
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http://www.biomedcentral.com/1471-2407/13/418is a differentiation marker of epithelial cells and plays an
essential role in the malignant behavior of breast tumors
[58]. Nearly 80% of breast carcinomas exhibit a loss of
the differentiation-associated keratin 8 and 18 have gen-
erally been associated with a worse prognosis [59,60].
Breast cancer cells become more aggressive andFigure 8 Effect of diets on expression of maspin and survivin in DMB
proteins as described in the text. Expression of maspin and survivin was de
were probed with β-actin antibodies for monitoring sample loading. Blotsmalignant with the loss of keratin as these proteins are
replaced with vimentin, the intermediate filaments-
protein of mesenchymal cells [61-63]. Experiments by
Buhler demonstrated that highly invasive MDA-MB-231
breast cancer cells became less invasive and lacked
tumorigenicity in nude mice with overexpression ofA-induced tumors. Frozen tumor tissues were used to extract
tected using specific anti-maspin and anti-survivin antibodies. Blots
represent two representative tumors from each group.
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http://www.biomedcentral.com/1471-2407/13/418keratin 18 [64]. It is, therefore, possible that DHA or
DHA +CCM treatment may have transformed DMBA-
induced tumors toward a more differentiated, less aggres-
sive subtype. Furthermore, immune histological analysis of
tumor tissues indicates that the DMBA-induced tumors
were ER-negative and Her-2 positive, further validating
the reported observations. We observed that DHA+CCM
treatment caused a significant expression of ER in DMBA-
induced tumors, further validating our observation of
microarray data in SK-BR-3 cells (Table 3). Reversal of the
estrogen negative to the estrogen positive phenotype has
previously been described [65]. This observation also sug-
gests that the combined treatment has induced differenti-
ation in breast tumors. We have not been able to further
characterize keratin or ER levels in these tumors due to
scarcity of the tissue; however, these observations also
need further investigation.
One of the observations from our microarray data was
the approximately 20-fold upregulation of SERPINB5
and almost 60% downregulation of BIRC5 genes.
SERPINB5 produces maspin, a tumor suppressor protein
present in high concentrations in normal mammary epi-
thelium and myoepithelium cells; maspin expression isFigure 9 Analysis of microarray data from SK-BR-3 cell line for interac
data from SK-BR-3 cell treatment with DHA, CCM, and DHA + CCM was use
regulatory mediators using MetaCoreTM version 6.3 (GeneGo). The interact
linked to activation of a number of caspase activities downstream for its prreduced in primary breast cancers and is completely ab-
sent in invasive and metastatic tumor cells [66,67]. Data
shown in Figure 8 indicate that maspin was absent or
expressed at low levels in the tumors of control or
DHA-fed animals. CCM treatment caused reexpression
of maspin, and this expression appears to be further en-
hanced by the combined DHA + CCM diet. Reexpre-
ssion of maspin in response to curcumin has previously
been shown in breast cancer cells by Parsad et al. [68].
Maspin is a key regulatory molecule for the normal
mammary gland and embryonic development [69]. The
expression of SERPINB5 is regulated at the transcrip-
tional level through elements in the maspin promoter,
particularly by p53 [70-72]. Maspin is present in the
cytoplasm, but it translocates to the mitochondria and
inhibits tumor progression through the mitochondrial
apoptosis pathway [73]. Analysis of the microarray data
for caspase-mediated downstream processes in SK-BR-3
cells, as shown in Figure 9, indicates that maspin expres-
sion was linked to the activation of a number of caspases
involved in apoptosis. Additionally, maspin has also been
shown to induce cell differentiation, which further con-
tributes to its anti-cancer effects [74,75]. Furthermore,tion of maspin up- and down-stream mediators. The microarray
d to determine the interaction of maspin with up- and down-
ions indicate maspin is regulated upstream by p53, whereas maspin is
ominent role in the induction of apoptosis.
Figure 10 The proposed signaling pathways for the synergistic
effects of DHA and CCM on progression. One possible
mechanism for the effects of CCM, DHA or CCM + DHA on p53
activation and/or PPARγ expression is to suppress the anti-apoptotic
protein, survivin, while increasing the expression of maspin, a tumor-
suppressor protein. This situation could lead to the induction of
apoptosis, thereby inhibiting tumor progression.
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http://www.biomedcentral.com/1471-2407/13/418PPARγ induced mammary cell differentiation, which is
also accompanied by enhanced maspin expression [76];
however, it is not known if PPARγ directly regulates
maspin expression in cancer cells.
BIRC5 produces survivin, the smallest member
(16 kDa) of the inhibitor of the apoptosis protein (IAP)
family, which acts not only to inhibit apoptosis but also
to control cell cycle progression [77-79]. Survivin is
largely expressed in developing embryos and proliferat-
ing hematopoietic, epithelial, and gonadal cells [80]. It is
mostly absent from well differentiated normal adult tis-
sues, but hyperplasic regions of normal tissues often
show some expression; however, survivin overexpression
has been reported in nearly all human cancers, including
breast cancer [80-82]. Data presented in Figure 8 indi-
cate that DMBA-induced tumors expressed substantial
levels of survivin. These levels were not affected by
DHA or CCM treatment, but a combined treatment
(DHA + CCM) caused almost a 50% reduction in sur-
vivin expression. Disrupting survivin expression or func-
tion in cancer cells has been shown to decrease cell
proliferation by enhancing apoptosis. Survivin has been
considered an effective target for anticancer strategies in
several preclinical and early-phase clinical trials [83].
Factors that are involved in regulating maspin re-
expression are also involved in regulating survivin ex-
pression. For example, nuclear factor kappaB (NFkB)
upregulates survivin expression [84], whereas p53 and
retinoblastoma protein (pRb) are required to repress
survivin transcription [85]. More recently, Verhagen
et al. reported that mutations of the p53 gene in breast
carcinoma significantly correlate with an enhanced ex-
pression of survivin [86]. In addition, PPARγ reduces
levels of survivin in different cancer types, including
breast cancer [87,88].
Previously, we demonstrated that DHA and CCM syn-
ergistically cause activation of p53 and upregulation of
PPARγ expression. Based on these observations, it is
possible that the effects of CCM+DHA on p53 activa-
tion and/or PPARγ expression cause suppression of the
anti-apoptotic protein, survivin, with increased expres-
sion of maspin, a tumor suppressor protein. This effect
would lead to the inhibition of cell cycle progression and
to the induction of apoptosis, thereby inhibiting tumor
progression (Figure 10). Clearly, additional experiments
are needed to confirm a role of p53 and/or PPARγ on
maspin re-expression and survivin suppression.
One limitation of this study is the low levels of linoleic
acid in DHA and DHA +CCM diets. High levels of lino-
leic acid have been shown to stimulate breast cancer
[89]. It is unlikely that low levels of linoleic acid have
any effect on the growth or number of breast tumors
since the DHA diet itself was not very effective. How-
ever, it is possible that reduced linoleic acid with CCMmay have played a role in the synergistic effect of the
DHA + CMM diet on breast tumor formation. Clearly,
further investigation is required to determine the com-
bined effect of a reduced level of linoleic and CCM on
breast cancer growth.
Conclusion
The data from this in vitro study is consistent with our pre-
viously published study. The results of this study further
demonstrated that the synergistic effects of DHA+CCM
were evident both under in vitro and in vivo conditions.
SK-BR-3 cells and DMBA-induced tumors, both with ER-
and Her-2+ characteristics, were synergistically affected by
DHA and CCM, which suggests that the specific breast
cancer phenotype is an important factor for predicting effi-
cacy. One possible mechanism for the synergistic effects of
DHA+CCM on ER-/Her-2+ breast tumors involves the
re-expression of maspin and the suppression of survivin.
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